💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Halofantrine

CHEMBL1107 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
500.4 g/mol
LogP
8.6
Phase
4

An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

Khối lượng phân tử

500,4000 g/mol

LogP

8,60

TPSA

23,50 Ų

Lipinski RO5

Không đạt

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Schizophrenia Generalized Anxiety Disorder Systemic Lupus Erythematosus Obesity Transplant Medicine Hypertension Major Depressive Disorder Breast Cancer Malaria HIV/AIDS Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12

                

                

                
                

                    
InChI

                    
InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H30Cl2F3NO

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
Liên kết có thể quay

                        
10

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Halofantrine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1107.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 37393.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.